# Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02182583** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 163 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Ba253MDI
- **DRUG:** Ba253BINEB

## Key facts

- **NCT ID:** NCT02182583
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-10
- **Primary completion:** 2000-06
- **Final completion:** —
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182583, "Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*